Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maze Therapeutics (MAZE) Equity Average (2024 - 2026)

Maze Therapeutics' Equity Average history spans 3 years, with the latest figure at $348.3 million for Q1 2026.

  • On a quarterly basis, Equity Average rose 3744.61% to $348.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $348.3 million, a 3744.61% increase, with the full-year FY2025 number at $21.9 million, changed N/A from a year prior.
  • Equity Average hit $348.3 million in Q1 2026 for Maze Therapeutics, down from $367.2 million in the prior quarter.
  • Over the last five years, Equity Average for MAZE hit a ceiling of $367.2 million in Q4 2025 and a floor of -$333.0 million in Q2 2024.
  • Historically, Equity Average has averaged $50.0 million across 3 years, with a median of $133.8 million in 2025.
  • Biggest five-year swings in Equity Average: surged 183.23% in 2025 and later surged 3744.61% in 2026.
  • Tracing MAZE's Equity Average over 3 years: stood at -$297.9 million in 2024, then surged by 223.28% to $367.2 million in 2025, then decreased by 5.14% to $348.3 million in 2026.
  • Business Quant data shows Equity Average for MAZE at $348.3 million in Q1 2026, $367.2 million in Q4 2025, and $320.8 million in Q3 2025.